Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD

被引：0
|
作者：
Hedegaard, Morten [1 ]
Janson, Christer [2 ]
Lisspers, Karin [3 ]
Stallberg, Bjorn [3 ]
Johansson, Gunnar [3 ]
Jorgensen, Leif [1 ]
Larssen, Kjell [4 ]
机构：
[1] Astrazeneca, R&D, Sodertalje, Sweden
[2] Uppsala Univ, Dept Med Sci, Resp Med, Uppsala, Sweden
[3] Uppsala Univ, Dept Publ Hlth & Caring Serv Family Med & Prevent, Uppsala, Sweden
[4] Karolinska Inst, Natl Inst Environm Med, Unit Lung & Allergy Res, Stockholm, Sweden
来源：
EUROPEAN RESPIRATORY JOURNAL | 2013年 / 42卷
关键词：
COPD; -; management; Exacerbation; Pneumonia;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
1999
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Maintenance and reliever therapy with budesonide/formoterol versus fixed dose fluticasone/salmeterol in patients with COPD
    Muiser, S.
    Imkamp, K.
    Seigers, D.
    Halbersma, N.
    Vonk, J.
    Luijk, B.
    Braunstahl, G.
    Van den Berg, J. W.
    Kroesen, B.
    Kocks, J.
    Heijink, I
    Reddel, H.
    Kerstjens, H.
    Van den Berge, M.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [32] Cost-effectiveness of fluticasone propionate/salmeterol (500/50 μg) in the treatment of COPD
    Earnshaw, Stephanie R.
    Wilson, Michele R.
    Dalal, Anand A.
    Chambers, Mike G.
    Jhingran, Priti
    Stanford, Richard
    Mapel, Douglas W.
    RESPIRATORY MEDICINE, 2009, 103 (01) : 12 - 21
  • [33] COMPARATIVE EFFECTIVENESS OF FIXED-DOSE FLUTICASONE PROPIONATE/SALMETEROL AND BUDESONIDE/FORMOTEROL COMBINATIONS IN ASTHMA: A US DATABASE ANALYSIS
    Hamouda, Mohamed
    Hanania, Nicola A.
    Stanford, Richard H.
    Rendon, Adrian
    Gemicioglu, Bilun
    Fritscher, Leandro
    Boonsawat, Watchara
    Khan, Shireen Quli
    CHEST, 2024, 166 (04) : 6461A - 6462A
  • [34] Budesonide/formoterol via the Elpenhaler® device in asthmatic patients: A real-world effectiveness study (The BOREAS Study)
    Bakakos, Petros
    Papakosta, Despoina
    Loukides, Stylianos
    PNEUMON, 2021, 34 (04)
  • [35] EFFECTIVENESS AND SAFETY OF INITIATING TREATMENT WITH FLUTICASONE/SALMETEROL VIA MDI VERSUS DPI IN COPD
    Jones, R.
    Martin, J.
    Thomas, V.
    Skinner, D.
    Marshall, J.
    Price, D.
    THORAX, 2015, 70 : A141 - A142
  • [36] Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials
    Halpin, D. M. G.
    Gray, J.
    Edwards, S. J.
    Morais, J.
    Singh, D.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (07) : 764 - 774
  • [37] Cost Effectiveness of Budesonide/Formoterol for Maintenance and Reliever Therapy versus Salmeterol/Fluticasone plus Salbutamol in the Treatment of Asthma (vol 24, pg 695, 2006)
    Johansson, G.
    Andreasson, E. B.
    Larsson, P. E.
    Vogelmeier, C. F.
    PHARMACOECONOMICS, 2008, 26 (10) : 894 - 894
  • [38] Mycosis induced asthma treatment: fluticasone/salmeterol vs. budesonide/formoterol reinforced by montelukast
    Sygaieva, Iryna
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [39] Effectiveness of Fluticasone propionate with Salmeterol on COPD symptoms treatment.
    Orefice, U
    Da Broi, U
    Talmassons, G
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A525 - A525
  • [40] Real-world effectiveness and safety of alirocumab
    Mondelo Garcia, C.
    Garcia Queiruga, M.
    Balea Filgueiras, J.
    Fernandez Bargiela, N.
    Gimenez Arufe, V.
    Fernandez Oliveira, C.
    Martin Herranz, M. I.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 377 - 378
12345